5:13 PM
 | 
May 06, 2013
 |  BC Extra  |  Top Story

Concert, Celgene partner

Celgene Corp. (NASDAQ:CELG) partnered with Concert Pharmaceuticals Inc. (Lexington, Mass.) to develop deuterium-modified compounds for cancer and inflammation. The deal...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >